We previously reported that 11 of 32 patients with IPF newly treated with nintedanib at a dose of 150 mg twice daily from September to December 2015 exhibited aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevation with the Common Terminology Criteria for Adverse Events (CTCAE) grade ≥26, 7. The gene discussed is GPT; the disease is idiopathic pulmonary fibrosis.